Researchers at the ESMO Congress presented data showing better responses on dual-checkpoint blockade in the biomarker-defined ...

Researchers reported at the ESMO Congress that 78 percent of patients responded to front-line treatment with Lumakras, Vectibix, and chemo.

The firm, in the midst of a Phase III trial testing a cell therapy for heart failure, has demonstrated compliance with Nasdaq's equity rule.

The French firm has a lead metastatic colorectal cancer vaccine candidate headed for Phase I/IIA trials, in which it will explore ways of predicting response.

The firms will collaborate on two lead programs and up to five future targets in other diseases, with NanoVation eligible for up to $600 million in payments from Novo Nordisk.

Analysis of ctDNA in the MARIPOSA trial showed fewer EGFR alterations and MET amplifications after Rybrevant-Lazcluze treatment than after Tagrisso.

Researchers analyzed molecular and particulate matter exposure data on nearly 9,000 NSCLC patients in France and confirmed a link reported by UK scientists in 2022.

Phase I data presented at ESMO suggested that TORL-1-23 may have particularly strong activity in CLDN-positive advanced ...

The firms will share data from the HERTHENA-Lung02 trial, in which patritumab deruxtecan improved patients' progression-free survival versus chemo.

The adaptive basket trial, which matches patients to treatments based on complex biomarker signatures, could help shape ...

Experts noted, however, there is insufficient evidence to determine which commercially available KRAS G12C inhibitor is the ...

The drug is approved in combination with an aromatase inhibitor as adjuvant therapy for breast cancer patients at high risk of recurrence.